Odyssey

Odyssey

Private
Boston, MassachusettsHealthcare & Life Scienceswww.odysseytx.com

Last Round

Series D

9/10/2025

Total Funding Raised

$700M

Company Overview

Odyssey Therapeutics is a biotechnology company focused on developing immunomodulators and oncology drugs to enhance drug discovery and expedite clinical development for next-generation precision therapies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials, ML Platforms

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Infrastructure

Keywords

AI drug discoveryprecision immunomodulatorstechbiosmall molecule therapeuticsdrug discovery platformundruggable targetsoncology medicinesin-silico drug discoveryinflammatory diseasesautoimmune diseasesRIPK2 inhibitorcomputational chemistryquantum machine learningprotein therapeuticsclinical-stage biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Odyssey Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Odyssey Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series D9/10/2025
IPO1/17/2025
Series C12/5/2023
Series B10/13/2022
Series A12/7/2021

Odyssey Investors

Notable investors and investment history

InvestorRounds
TPG Life Sciences InnovationsSeries D
GreatPoint VenturesSeries B
CPP InvestmentsSeries C
Wedbush Healthcare PartnersSeries D
KB InvestmentSeries C
Frontline BioVenturesSeries B, Series C, Series A
The Healthcare Innovation Investment Fund LLCSeries B, Series C

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 21, 2026

    Jolie M. Siegel appointed Executive Vice President, General Counsel.

  • Nov 11, 2025

    Dennis Dean appointed EVP and Head of Non-Clinical Development.

Odyssey Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Odyssey Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Odyssey's valuation, stock price, and market status.

Firmographic Details

HeadquartersBoston, Massachusetts
Employee Range117
Year Founded2018
Last Funding9/10/2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







DisclaimerAll investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.